VTRS Q1 2023 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.7B-11.0% YoY

Gross Profit

$1.5B41.4% margin

Operating Income

$400M10.7% margin

Net Income

$225M6.0% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

-3.8%

Cash Flow

Operating Cash Flow

$971M

Free Cash Flow

$889M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$49.3B

Total Liabilities

$28.4B

Stockholders' Equity

$20.9B

Cash & Equivalents

$507M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$4.2B	-11.0%
Gross Profit	$1.5B	$1.8B	-12.9%
Operating Income	$400M	$707M	-43.5%
Net Income	$225M	$399M	-43.7%

Revenue Segments

Brands

$2.4B65%

Generics

$1.2B31%

Complex GX and Biosimilars

$136M4%

Geographic Segments

Developed Markets Segment

$2.2B58%

Emerging Markets Segment

$642M17%

Greater China Segment

$565M15%

Japan, Australia and New Zealand Segment

$342M9%